Ergo Science, Inc. v. Martin

CourtCourt of Appeals for the Fifth Circuit
DecidedJanuary 29, 1996
Docket94-11107
StatusPublished

This text of Ergo Science, Inc. v. Martin (Ergo Science, Inc. v. Martin) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ergo Science, Inc. v. Martin, (5th Cir. 1996).

Opinion

UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

__________________

No. 94-11106 __________________

ERGO SCIENCE, INC.,

Plaintiff-Appellee,

versus

DONN D. MARTIN, ET AL.,

Defendants,

ELITE THERAPEUTICS, INC.,

Defendant-Appellant.

HOMER WEST, ET AL., Claimants-Appellees.

* * * * * * * * * * *

No. 94-11107 __________________

IN RE: Distribution of Funds Paid by Ergo Science Incorporated Into Registry of Court in No. 4:92-CV-917-A

Appellant.

______________________________________________

Appeals from the United States District Court for the Northern District of Texas ______________________________________________ January 26, 1996

Before WIENER, EMILIO M. GARZA and BENAVIDES, Circuit Judges.

BENAVIDES, Circuit Judge:

The central issue in this appeal is whether a district court

can rely upon statements made by counsel in open court disavowing

any interest in an interpleaded fund. Because as a matter of

federal civil procedure a district court can hold counsel to his

word, we affirm.

FACTUAL AND PROCEDURAL BACKGROUND

This controversy is rooted in a contract dispute between Ergo

Science Incorporated ("Ergo") and appellant Elite Therapeutics,

Inc. ("ETI"). Ergo holds the license for commercial development of

certain medical technologies for the treatment of obesity and

diabetes. ETI alleged that it purchased the right to sublicense

these technologies. Ergo denied this allegation contending that no

such sublicense existed. It is undisputed, however, that ETI paid

Ergo $1,050,000; these funds were raised by ETI from investors.

This appeal surrounds an interpleader action concerning these

funds.

In 1992, Ergo sued ETI and its president Donn Martin seeking

a declaratory judgment that no sublicense agreement existed. Ergo

later amended its complaint to include, inter alia, an interpleader

claim. Ergo alleged that it learned from certain investors that

ETI and Martin solicited the funds paid to Ergo by falsely stating

that ETI already had a sublicense for the technologies when in fact

the parties were merely negotiating. In the interpleader action,

2 Ergo contended that some 500 individual investors, who were

defrauded by ETI, were third-party claimants to the fund.

On October 28, 1994, the district court conducted a hearing on

the interpleader claim. At this hearing, Ergo unequivocally waived

any interest in the $1,050,000 which it paid into the registry of

the court. Counsel for ETI, however, made conflicting statements

regarding the funds. Counsel repeatedly stated that the money

belonged to Ergo because of the alleged sublicense agreement. At

one point, counsel stated that if there was no contract, the money

belonged to ETI. However, after some discussion as to whether ETI

had filed a claim to the fund the court directly asked ETI:

If Ergo says I can give it to the investors, they wash their hands of it. You say your clients wash their hands of it, I give it to the investors. Then it's a matter of me sitting down with the investors and trying to work out a way to distribute it. Are we at that point?

Counsel for ETI answered: "Yes. That's fine with me, your Honor."

After this colloquy, the court discussed with counsel for the

investors-claimants possible procedures for pro rata relief.

Following this hearing, the district court ordered that Ergo,

Martin, and ETI "all disclaimed any claim to or interest in the

funds that Ergo has interpleaded into court in this action."

Furthermore, the court found that "Martin and ETI acknowledged that

they have made no claim to such funds; and, Ergo, Martin, and ETI

all agreed that the court can order that the proper claimants to

such funds are those parties to this action who . . . have asserted

in this action claims to such funds." In addition, the court

determined that "there is no just reason for delay in, and hereby

directs, entry of final judgment as to the rulings made by the

3 court in this order." Simultaneously, the court issued a final

judgment that Ergo, ETI and Martin had no interest in the

interpleaded fund.

On December 21, 1994, ETI filed a Rule 60(b) motion for relief

from the judgment on the grounds that the district court was

mistaken when it concluded that ETI had waived all claims to the

funds. The district court concluded the motion was meritless

because, based upon the record of the hearing, ETI's counsel

relinquished any claim to the funds in open court. This appeal

ensued.

Prior to oral argument, Ergo and ETI settled their underlying

dispute. Likewise, ETI and the bulk of the investors-claimants

reached a settlement. However, one group of investors, the Barrett

group, did not settle; there remains an on-going dispute between

the Barrett investors and ETI. Consequently, this remaining

controversy breathes life into the arguments originally raised by

Ergo and the rest of the investors-claimants.

JURISDICTION

As a threshold matter, our jurisdiction to entertain this

appeal has been challenged on two grounds.1 Initially,

jurisdiction is challenged because ETI lacks standing since it

The jurisdictional issues were first raised by Ergo in a motion to dismiss the appeal. We carried this motion to the merits. The investors-claimants then adopted Ergo's argument by reference. The Barrett group has in turn adopted the arguments raised by the investors-claimants. Since Ergo has settled its dispute with ETI, its motion to dismiss for lack of jurisdiction is denied as moot. Nonetheless, we briefly address the jurisdictional issues initially raised by Ergo and later adopted by the Barrett group to determine our jurisdiction with respect to these remaining appellees.

4 disavowed any interest in the interpleaded funds. Secondly,

appellees contend that the district court's orders are

interlocutory. We reject both of these arguments.

As for standing, appellees rely on our recent opinion in Rohm

& Hass Texas, Inc. v. Ortiz Bros. Insulation, Inc., 32 F.3d 205,

209-12 (5th Cir. 1994). Rohm, however, is not controlling. In

Rohm, it was the plaintiff-stakeholder who sought to appeal. We

dismissed the appeal because the stakeholder had unequivocally

denied any interest in the fund, continued to disavow any interest

on appeal, and sought merely to prevent some possible future

indirect injury from the court's priority in distribution. The

situation presented here is quite different. This dispute involves

a potential claimant to the fund, not the stakeholder, and the very

issue on appeal is whether ETI has waived its interest in the

interpleaded funds or not. The district court's judgment decrees

that ETI has no interest or right to the interpleaded funds. ETI,

therefore, has standing to challenge this order because it is not

faced with a hypothetical or indirect injury as in Rohm, but a real

and immediate injury.

This court also has jurisdiction over the appeal because it

involves a final judgment under Federal Rule of Civil Procedure

54(b). This rule provides that:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Ergo Science, Inc. v. Martin, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ergo-science-inc-v-martin-ca5-1996.